Podcasts about Hepatitis B

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Anonymous: Good day Dr.Cabral, your doing great work! Can't imagine how proud your family and team are to have you. My question is regarding elevated CRP (didn't do HS-CRP) just did bloodwork for CRP. Which was 13. Also Lip (a) is 180.. which is high due to genetics. In combination.. A1C is creeping up at 6.1.. I know your not giving health advice however, what foods, products help? Berberine? Omega 3s? Thanks!       Matthew: Hi Dr Cabral-thanks for everything you do. My question is on turmeric. I have seen posts that turmeric supplements, especially those that also contain black pepper, are harmful to the liver. Do you agree? If so, what about turmeric that do not include the black pepper? If turmeric supplement's harm to the liver is higher than the benefit, do you have suggestions on a replacement? Thank you     Jasmine: I think my daughter has Lipedema, I've watched a few of your videos and have researched this topic but have never had this topic addressed: she drinks about a liter and a half of water a day, but doesn't urinate that much, never gets up at night, can go the whole day without. Is this affecting her Lipedema and any info you can share, your ideas/opinions would be appreciated. We do things holistically, no drugs unless absolutely necessary (emergency situations), and I don't think diuretics are the way to go. Thanks for any info, Jasmine       Andrea: Hi Dr. Cabral, What is your opinion of the laser therapy for the brain for improved cognition, lymphatic flow? I was made aware of PBM would love to know your opinion. Thanks for everything, grateful for you!       Anonymous: Good morning Dr.Cabral, How would you go about supporting the body naturally dealing with Hepatitis B (chronic).. This has unfortunately been undetected for years due to being born in East Africa. In turn, this long-term Hep B has lead to Hepatocellular caricoma.. However, after a lot of research, the root cause was the Chronic Hep B.. want to deal with this then support the body to shrink the liver mass. Thoughts? Not asking for medical advice. did the HTMA (was unremarkable) but noticing a bit of itching and upper abdominal pain.         Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!      - - - Show Notes and Resources: StephenCabral.com/3851 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Broadcast from KSQD, Santa Cruz on 8-20-2026: An emailer asks about amlexanox for mast cell activation syndrome (MCAS). Dr. Dawn first walks through MCAS diagnostic criteria—requiring symptoms across at least two of four categories (skin, low blood pressure, abdominal, respiratory), with serum tryptase testing performed both during and after a flare. She grades amlexanox as a C: originally FDA-approved only as a topical paste for canker sores, later approved in Japan as an asthma treatment, but never validated for MCAS and pushed largely by a single compounding pharmacy and its influencer clones. She recommends conventional agents first—antihistamines, montelukast, cromolyn, quercetin, aspirin for flushing, and Xolair anti-IgE antibodies for severe cases—plus microcrystalline cellulose as the safest capsule filler if compounding of amellanox is pursued. Most ovarian cancers—including nearly all fatal cases—actually originate in the fimbriae of the fallopian tubes rather than the ovaries themselves. Opportunistic salpingectomy tacks a five-minute fallopian tube removal onto any abdominal surgery (tubal ligation, hernia repair, gallbladder, appendectomy), potentially reducing lifetime ovarian cancer risk by 65% -80% based on epidemiological data from Swedish, Canadian, and Danish registry studies. Dr. Dawn recommends particular consideration for non-childbearing women with BRCA1/2 or family history of breast or ovarian cancer. Deep brain stimulator devices manufactured after 2020 (about 40,000 U.S. patients) contain adaptive-DBS capability that can be activated via firmware upgrade without additional surgery. Rather than delivering constant stimulation like older devices, adaptive DBS reads beta oscillations (13-30 Hz motor-control brainwaves) in the basal ganglia and modulates output in real time—reducing stimulation as L-DOPA peaks from drugs and increasing it as medication wears off, smoothing the swings between agitation and freezing. Sleep improvement has emerged as a notable secondary benefit, potentially slowing disease progression. The technology is also being investigated for dystonia, essential tremor, OCD, and Tourette's syndrome. Chinese company StarMed is developing brain-computer interfaces closely resembling Neuralink designs, benefiting from aggressive government funding, large patient populations, and reduced tort liability. One trial uses an eight-probe device placed atop the dura mater (avoiding brain penetration) connected to a pneumatic glove that has restored eating and drinking function in about twenty paralyzed patients over twenty months. A more invasive Shanghai trial implanted 256 probes on the neural cortex of a woman with epilepsy who could operate social media and control a wheelchair within two weeks; a related U.S. system using 65 hair-thin sensors enabled speech with just ten-millisecond delay. An emailer describes recurring two-week viral illnesses (sore throat, swollen glands, congestion, cough, body aches) recurring every 4-6 weeks. Dr. Dawn frames the question as either impaired immunity or changed exposure. She recommends starting with a CBC to rule out blood dyscrasias like leukemia, checking urine mycotoxins for mold exposure, then examining behavioral changes—new job, handling cash before eating, and the well-documented protective effect of masking in public that dramatically reduced cold rates during COVID. Dr. Dawn covers three health policy items. The good: new USDA dietary guidelines flip the food pyramid, putting protein, dairy, healthy fats, vegetables, and fruits at the top, with whole grains reduced to a small band, and it's recommendation 1.2 g/kg protein daily. The bad: an executive order attempting to reduce childhood vaccines from 18 to 11 and separate MMR into individual components—impossible since no U.S. manufacturer makes the individual antigens, and misguided since infant hepatitis B vaccination prevents mother-to-child liver cancer transmission. The ugly: a 26-year-old heart transplant recipient whose insurer initially dropped coverage of her generic anti-rejection drug, then "ghost approved" it at $1,000 for 90 days versus the previous $180. Mark Cuban's Cost Plus Pharmacy now supplies her the same medication for $300 (cost plus 15% profit plus 5% handling), highlighting the massive markups embedded in the standard pharmacy chain. For a time before that, the mother of the heart donor stepped up and paid for the recipients anti-rejection drugs to keep her son's heart beating.

This week we talk about the liver, viral infections, and the NHS.We also discuss blood scandals, needle usage, and Nobel Prizes.Recommended Book: A World Appears by Michael PollanTranscriptThe term “hepatitis” refers to the inflammation of the liver, which can result from all kinds of things, including environmental toxins, the consumption of alcohol, or autoimmune diseases. It can also result from viral infections, and the most prominent liver-inflaming viruses are called viral hepatitis.There are five types of viral hepatitis, A, B, C, D, and E, and each of these viruses are distinct, not part of the same viral family, they're just similarly named because they impact the same organ.Hepatitis A and E are primarily spread through contaminated food and water, and generally resolve on their own, untreated, and cause relatively mild symptoms. Hepatitis B and C are spread through blood and other bodily fluids, and can linger in a host's body for decades before even showing symptoms. Hepatitis D is a parasite of Hepatitis B, and thus only infects people who carry Hepatitis B.Now again, these are all different conditions that just happen to inflame the liver, so impact and treatment also vary quite a lot. As I mentioned, A and E generally present with mild symptoms and tend to go away on their own, while B and C can stick around a long time. There's a vaccine for B, but no cure; you can treat it, but that treatment involves suppressing it, and keeping it suppressed, forever. Hep C, in contrast, is curable, and has been since 2014 using what are called direct-acting antiviral pills, but these pills, which are taken for 8 to 12 weeks, are expensive—ranging from $22-95k without insurance, though that price is often reduced substantially for those with insurance, down to as low as $5. This category of drug coverage is often rejected by insurance companies, though, in part because they're so expensive, that expense the result of little competition in this space; few companies make this type of drug, so those that do can charge more or less whatever they like.Some people with Hepatitis C clear it on their own; about 30% of people who contract it, in fact, clear it within a few months, medication-free. Which is good, because our understanding of this virus is relatively new. Up until 1989, Hep C didn't even have its own name: it was established as its own thing, not Hep A and not Hep B, back in the 1970s, and doctors knew that something that wasn't those two viruses, that was being spread by transfusions, was causing hepatitis symptoms, but they didn't know any real specifics, so they just called it “non-A, non-B hepatitis,” and that name stuck for more than a decade.In 1989 the virus was cloned using molecular techniques (as opposed to simply growing the virus, which wasn't proving fruitful in trying to isolate and identify the thing), and the folks who managed that cloning, and the person who later proved that the genome they cloned, alone, caused the disease, received a Nobel Prize in Medicine for their efforts in 2020.By 1991, antibody tests were available for Hep C, and many countries began screening donated blood for this virus, to ensure it wasn't working its way into their blood supply.And one instance of that screening process, or I suppose, an event that led up to mass screening, and the consequences that followed, are what I'd like to talk about today. The UK's efforts in trying to eliminate Hep C, and England's recently announced near-success in that pursuit.—Hepatitis C is an RNA virus with high genetic variability that makes developing a reliable vaccine difficult. And though somewhere between a quarter and a third of all cases clear on their own, those that don't clear on their own become chronic, lying in wait for twenty to thirty years, slowly accumulating fibrosis—thick scar tissue in the liver—which eventually results in cirrhosis, which means a liver that's so heavily scarred that the organ is no longer fully functional and the damage is permanent. From there, infected people often experience liver failure or hepatocellular (huh-pah-toe) carcinoma, liver cancer.So this virus is a sleeper, and unless it's caught by accident somewhere along the way, it slowly causes damage over time until the damage is too severe to reverse. About 80% of people who have it don't know they have it, and in some parts of the world medical injections are the most common transmitter, but in higher-income areas, it's usually transmitted by injectable drugs.Pre-2014 treatments for Hep C were pretty horrible, involving a combination antiviral therapy called pegylated interferon plus ribavirin that was injected weekly for six months to a year, and this was terribly tolerated by pretty much everyone, causing anemia, depression, and flu-like symptoms for the duration. It also only cured about 50% of people who received the full treatment, and a lot of people had to stop because it caused such ridiculous side effects.Another antiviral called Sofosbuvir (so-FAS-buh-vir), which kept Hep C from replicating in its host, hit the market in late-2013, and that led to a series of direct-acting antivirals that reduced the treatment period dramatically, allowing most people, 95%, to cure their Hep C entirely by taking generally well-tolerated pills for 8 to 12 weeks.These pills were staggeringly expensive from the get-go, with an entire treatment course initially costing about $84,000, or $1,000 a pill. This led to rationing, and saving these pills for the worst-impacted people who already had severe liver damage. There were also pretty stringent requirements attached to their distribution, including that people who received them could no longer drink alcohol, because it was considered a waste to give these crazy expensive, liver-saving drugs to people who would just go and hurt their liver more, anyway.In the UK, the demand for this treatment type was different than in most other countries, in large part because of something that happened back in the 1970s and 80s.The UK's publicly funded healthcare system, the NHS, was in the midst of a shortage of clotting factor, which are plasma proteins and ions that help blood clot and which are used for medical purposes. So they imported a bunch of plasma products from the US, and those products were sourced from the blood of paid donors—and that donor pool included prisoners and people who used injectable drugs. Just one Hep C contaminated blood donation could contaminate an entire batch of blood, and remember, they only started screening the blood supply for Hep C in 1991, and they didn't start treating their blood supply for Hep C until a little before that, 1985, so this was well before they had any idea what was in those blood products they were importing and administering.Consequently, between 1970 and the early 1990s, more than 30,000 NHS patients received transfusions or other blood product treatments contaminated with Hep B, Hep C, or HIV, and about a tenth of those people, around 3,000 patients, have since died of those conditions.The UK government leaned on denial and a refusal to look into the details of this for years, but in 2017 it announced an independent public inquiry into the matter, and in May of 2024, that inquiry concluded that this whole scandal was avoidable, that patients were knowingly exposed to “unacceptable risks,” and that there was a big cover up by government officials, doctors, and other people working with the NHS.As of mid-2026, only a little over 3,200 people of the more than 18,500 who registered claims, demanding compensation from the government because they were impacted by this scandal, have been paid out. The expected total expense for the UK government is on the order of 12.8 billion pounds, but a lot of people who are probably due a payout, and who are in poor and deteriorating health as a consequence of all this, don't yet have a sense of when they'll receive their payment.Back in 2016, before all that came to a head, the UK set itself an aggressive goal: to eliminate Hep C by the WHO's 2030 target, or before. It then ran a competitive tender for antivirals, inviting medical suppliers to submit competing bids, resulting in the largest single medicine procurement program in the NHS' history. The pharmaceutical companies that won their bids were also obliged, as part of the agreement, to help fund efforts to identify undiagnosed but infected patients, in addition to supplying antiviral pills, and this combination of investment and application led to the deployment of new tests and scanning machines, free postal test kits, the hiring of specialists, and services that focused on prisons and drug users.The impact of all this has been significant: a more than 61% decline in infections from 2015 to 2024, nearly half of all drug users with Hep C had cleared the virus in that time, and deaths from Hep C are down 36% over the past decade.The WHO treatment-coverage target—the percentage of people who are diagnosed getting treatment—was 80%, and England has hit 81.5%, which was recently announced to much fanfare. It hasn't yet hit the diagnosis target, however, which is to diagnose 90% of people who are estimated to have Hep C; they've hit 84.6%, which is still quite a lot of progress, even if they're not yet where they'd like to be. That's all based on models, of course, as are the assumed number of infections among people who use injectable drugs, which is also a spot where England is currently flagging; there's no centralized system in England to monitor needle and syringe provisions, and reinfection rates are around 8.8 per 100 person-years among people who had injected within three years of receiving treatment, and that rate is even higher for people who have ever been to prison, around 9.4 per 100.What that means in practice is that the English government overall has done a pretty astounding and effective job at negotiating their relationships with pharma companies and getting detection on track at that scale, but on more ground-level issues that are, interestingly, a lot cheaper to implement, but at times more politically complicated because of public sentiment about drug use and drug users, they're doing a lot less well—and important to note here is that these outcomes vary a bit across the four programs being run across the UK. Scotland and Wales are doing relatively better and worse in some regards compared to England, for instance.Also worth noting here that while England is broadly doing a great job with Hep C diagnosis and treatment, they aren't the first to achieve those WHO-set goals: Egypt reached Gold tier status according to the WHO's Hep C guidelines in October of 2023, at that point having diagnosed 87% of people who have the virus, and treating 93% of those who were diagnosed. They managed to cut incidence of the virus by 97% in just 8 years, leaning on a system of high-yield testing—they tested more than 60 million people during those 8 years—alongside a production scheme that included local manufacturing of antivirals, making them more available and affordable.All of which are generally good signs about where Hep C testing and treatment is going, at least in these regions. And it paints a optimistic picture for other countries that might want to replicate some of what's working within their own borders.Show Noteshttps://www.bbc.com/news/articles/c75gk620r22ohttps://en.wikipedia.org/wiki/Infected_blood_scandal_in_the_United_Kingdomhttps://en.wikipedia.org/wiki/Hepatitis_Chttps://en.wikipedia.org/wiki/Viral_hepatitishttps://en.wikipedia.org/wiki/Hepatitis_Bhttps://www.healthline.com/health/hepatitis-c/treatment-costshttps://www.who.int/news-room/fact-sheets/detail/hepatitis-chttps://publichealthscotland.scot/publications/surveillance-of-hepatitis-c-in-scotland/surveillance-of-hepatitis-c-in-scotland-progress-on-elimination-of-hepatitis-c-as-a-major-public-health-concern-2025-update/https://www.emro.who.int/media/news/egypt-becomes-the-first-country-to-achieve-who-validation-on-the-path-to-elimination-of-hepatitis-c.htmlhttps://www.gov.uk/government/publications/hepatitis-c-in-england-and-the-uk/hepatitis-c-in-england-2025https://www.england.nhs.uk/2026/08/100000-people-receive-treatment-to-cure-deadly-hep-c-virus-on-nhs-in-just-ten-years/https://www.hepctrust.org.uk/blog/2019/04/hepatitis-c-trust-welcomes-elimination-deal-hepatitis-c-and-calls-government-backed/https://commonslibrary.parliament.uk/research-briefings/cbp-10099/https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/reports/global-hepatitis-report-2026 This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

This week on Wellness Talk, George takes a closer look at President Trump's new executive order aimed at overhauling the childhood vaccine schedule. The order calls for a reduced list of routine childhood vaccines, greater spacing between vaccinations, and changes to the way combination vaccines such as MMR are administered. George breaks down what the executive order actually says, what could change for parents, and the questions it raises about childhood immunization policy.George also takes a closer look at how vaccine safety is tested and evaluated, using the hepatitis B vaccine as one example. What happens during clinical trials? What safety information is collected before approval, and what happens after a vaccine reaches the public? The segment examines the evidence, the testing process, and some of the questions parents may have about vaccine safety. Hepatitis B vaccines have undergone clinical evaluation, and safety continues to be monitored after approval through post-licensure surveillance.In the second half of the show, John begins a new series exploring The Way to Happiness: A Common-Sense Guide to Better Living. John starts with the opening section of the booklet and discusses its central concepts, why personal responsibility and everyday choices matter, and how these ideas can be applied to building a happier and more productive life.From current events and health policy to practical principles for living a better life, this week's Wellness Talk brings two very different conversations together—encouraging listeners to ask questions, examine the information, and think about the choices that shape their health and their lives.Listen, share, and join the conversation on this week's Wellness Talk!*This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician.

"People say 'I believe in vaccines.' Nobody says that about seatbelts." Aaron Siri is the managing partner of Siri & Glimstad and, by most measures, the most consequential vaccine litigator in America. He's the attorney behind the famous nine-hour deposition of Dr. Stanley Plotkin — the man they call the godfather of vaccines — lead counsel for the Informed Consent Action Network (ICAN), a 2025 Senate witness, and a central legal figure in the RFK-era reshaping of federal vaccine policy. His new book is Vaccines, Amen: The Religion of Vaccines — in his words, "a cross-examination in book form." This one steps outside the show's usual lane, and I want to be upfront: this is not medical advice, I'm not a doctor, and everything Aaron argues here is his own case — where it's contested by public-health bodies, treat it as one side of an open debate. What ties it to this show is the question we always ask: how do you know what's real when you're not allowed to check? From there we go deep — how a custody case led to the legendary Plotkin deposition; the Hepatitis B shot Aaron says was licensed on a trial of 147 kids, five days of monitoring, and no control group; the 1986 law he calls "the original sin" that handed vaccine makers liability immunity; the Ford Pinto and what punitive damages actually do; informed consent versus the right to refuse; whether vaccines really stop transmission; and the measles-mortality data he argues almost no one talks about. A conversation about evidence, incentives, and who gets to audit the people in charge. Subscribe so you never miss an episode.

Send us Fan MailIn this episode of Neo News, Ben and Eli break down a troubling story in vaccine policy: an unsolicited $1.6 million CDC grant funding a Danish research group's trial in Guinea-Bissau, one designed to withhold or delay the hepatitis B birth dose from thousands of newborns in a country where the disease is highly endemic. They trace the ethical parallels to Tuskegee, the funding irregularities, and the pushback from the Africa CDC that halted the study. They also cover the clinical stakes clinicians face daily, including age-dependent chronicity and the real risks of a "safe" two-month delay. A candid, unfiltered conversation about advocating for evidence-based care when the evidence itself becomes politicized.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In this episode, we spoke with Dr. Tatyana Kushner, Associate Professor of Medicine in the Department of Gastroenterology at Weill Cornell Medicine in New York. Dr. Kushner discusses hepatitis B treatment during pregnancy, including when antiviral therapy is recommended to help prevent mother-to-child transmission, and the importance of continuing hepatitis B care and treatment after pregnancy to support long-term liver health.Support the showOur website: www.hepb.orgSupport B Heppy!Social Media: Instagram - Twitter - Facebook

Hepatitis zählt zu den gefährlichsten Infektionskrankheiten weltweit – und bleibt doch oft lange unentdeckt. Im Hörgang der MedUni Graz erklärt die Hepatologin Vanessa Stadlbauer-Köllner, warum insbesondere Hepatitis B und C noch immer ein großes Gesundheitsproblem darstellen. Viele Betroffene wissen nichts von ihrer Infektion, weil die Erkrankung oft jahrelang ohne klare Symptome verläuft. Dabei können die Folgen schwerwiegend sein: Leberzirrhose, Leberkrebs und andere Komplikationen. Die Expertin spricht über aktuelle Entwicklungen bei Prävention und Therapie, über wirksame Impfungen gegen Hepatitis A und B sowie über die nahezu vollständige Heilbarkeit von Hepatitis C. Zudem zeigt sie, warum flächendeckende Tests und bessere Gesundheitskommunikation entscheidend sind. Eine Folge über eine stille Krankheit, die jeden treffen kann – und über die Chancen, sie rechtzeitig zu erkennen und zu verhindern.

Q-Bank: https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Liver Function Tests (1:42),Hepatitis A (4:33),Hepatitis B (6:02),Hepatitis C (8:44),MASLD (10:51),Alcoholic Liver Disease (12:11),Autoimmune Hepatitis (13:29),Acetaminophen Toxicity (14:53),Wilson Disease (15:55),Hemochromatosis (17:28),Cirrhosis (18:48),Ascites (20:59),Esophageal Varices (23:36),Hepatic Encephalopathy (24:54),Hepatorenal Syndrome (26:31),Hepatocellular Carcinoma Screening (27:52),Practice Questions (28:39)

The Root Cause of the Churban Welcome to Daily Bitachon. Today, we are discussing the Churban Beit Hamikdash (the destruction of the Holy Temple). While the Gemara provides many different reasons and causes for this tragedy, there is one famous cause mentioned by the Prophet Yeshaya ( Yeshayahu ) that, at first glance, seems remarkably minute. Speaking in the name of God, the prophet states: "Yaan כי נגש העם הזה ( Because this nation has approached Me ), befiv uvisfatav kibduni ( with their mouths and their lips they have honored Me ), but libo rishak mimeni ( their heart is far away from Me ), ותהי יראתם אותי מצות אנשים מלמדה ( and their fear of Me is just a commandment of men learned by rote )." The prophet concludes that because of this mechanical, rote behavior, the Beit Hamikdash was destroyed. At first glance, this is difficult to comprehend. It seems incredibly harsh to destroy the Holy Temple simply because people are performing mitzvot out of habit. Even if it is a flaw, it hardly seems like a crime—let alone one warranting such a severe punishment. Nobody killed, nobody stole; they were actively serving God, they just lacked heart. It was what we call "lip service"—mouths and lips moving, but no heart behind them. The Death of a Nation To understand this connection, we have to look at how the Kuzari describes the Churban Beit Hamikdash . He explains that the destruction of the Temple was, in a sense, the death of the Jewish nation. When the Beit Hamikdash was destroyed, we essentially lost our collective soul. The Kuzari compares our ongoing exile to a buried body that slowly decomposes over time until only dust is left—which is the exact stage we find ourselves in today. We are like "corpse dust." It is a remnant that still originates from a living body—it contains traces of DNA and RNA, meaning it isn't a mere rock or a plant—but it is the leftover remains of a human being. Ultimately, however, it can be reconstituted. When a person dies, medical records might list the cause of death as heart failure, kidney failure, liver failure, or brain failure. The vital organs simply shut down. But suppose the root cause of all that organ failure was Hepatitis B. If you ask the ICU doctors why the patient died, they will list the organs that failed. But if you want to know what actually killed him, you might find out that weeks prior, he was sitting at a fair and someone sneezed near a cherry, contaminating it. The man ate the cherry, caught the virus, and slowly deteriorated. If you say, "Come on, cherries don't kill people," it sounds extreme and far-fetched—unless you understand how microscopic bacteria and viruses work. The same principle applies to the death of a nation. The ultimate catalyst is rarely something open, obvious, or dramatic. The final outcome is clear, but Chazal (our Sages) wanted to unearth the microscopic root cause. For instance, the Gemara notes elsewhere that the land was lost because the people did not recite Birkat HaTorah (the blessing over the Torah) before studying. That seems like a minute detail. It wasn't the immediate cause of death, but it was the microscopic beginning. That initial lack of respect for the Torah was the contamination that eventually grew into total system failure. A Fruit Peel Without the Fruit What exactly is so deeply flawed about lip service that it could trigger such a catastrophic downfall? In Shaar Cheshbon HaNefesh , the Chovot HaLevavot provides a famous mashal (parable). He explains that a prayer without heart is like a fruit peel without the fruit, or a body without a soul. A body without a soul is a corpse; a fruit peel without the fruit is an empty facade. The Parable of the Empty Fruit Imagine a man who wants to honor the king. He prepares a lavish bowl filled with the most exotic fruits imaginable: out-of-season watermelons, mangoes, pineapples, dragon fruit, and lychees. The king is incredibly excited. But when he cuts into the watermelon, it's completely hollow. He cuts open the mango, and it's empty. They are nothing but empty shells without any substance. The Chovot HaLevavot says that this is exactly what happens when we pray without heart. It is a shell. Our bodies are there, our lips are moving, and our frames are swaying, but we are not actually there. We have checked out, we are thinking about something else, and our minds are somewhere else entirely. This hollow performance isn't limited to prayer; it shows up across a whole host of areas. The Beis Halevi and the Chovot HaLevavot both note that the same thing happens with bitachon (trust in God). You can easily sing songs about bitachon , but have absolutely nothing shifting inside your heart. God wants the heart— Rachmana liba ba'ei . An external shell without internal devotion is worthless. The Already-Ground Flour Rav Shlomo Wolbe explains this concept using a well-known Gemara. The Sages tell us that when the enemy breached the walls and destroyed the Temple, a heavenly echo ( Bat Kol ) rang out and said: Kimcha techina tachanta — "You have ground flour that was already ground." The voice was telling the invaders, "Do not think you are the ones who destroyed the Beit Hamikdash. It was already destroyed." What does it mean that it was already destroyed? It means the Beit Hamikdash had already become an empty shell. The Shechinah (Divine Presence) had already departed; the building was just an edifice without a soul. And why did the soul of the Temple leave? Because the Jewish people were living without heart and soul. The physical state of the Beit Hamikdash simply mirrored the spiritual state of the nation. Practical Takeaway Being involved in mitzvot without heart is a profound danger. The Chovot HaLevavot dedicated his entire masterpiece, Duties of the Heart , to this single premise: we cannot suffice with just doing things mechanically; we must put our hearts into them. As we approach Tisha B'Av, we will be focusing heavily on this topic. If we want to know how to heal the Churban , it is wonderful to say we want to be vigilant against heart attacks and organ failure. But real vigilance means making sure our "cherries" are clean before we eat them. We have to work on these microscopic, early root causes—beginning with moving past rote behaviors and bringing our hearts back to our service of God.

This week we welcome back our Paediatrician Expert Dr Lexi Frydenberg to help us understand what tests are routinely conducted when your baby is born.When your newborn arrives, they undergo a series of tests to ensure they are fit and healthy or to see if any interventions are necessary for their health. In this week's episode we unpack exactly what those tests are and what's involved.We discuss:- The APGAR test - what it is and how your baby is scored 1 minute after being born and again at 5 minutes- What the 5 key components of the APGAR score are- Why a scale is used for the APGAR score and what it means for your baby if they are given a low score- When your baby is born your baby will be checked head to toe to ensure everything is as it should be. We discuss in detail the examination of the baby's heart and lungs, hips, eyes, and spine- Why oxygen saturation is checked and how this is tested- The Heel Prick test - what the test is, how the test is conducted and what potential serious disorders are screened for - Newborn hearing tests - what is involved, and why it is tested in hospital- We discuss newborn immunisations (Vitamin K and Hepatitis B) and why you might consider these- Dr Lexi shares her tips and tricks to help babies and parents with newborn screening tests.Never forget Parents You've Got This Parents You've Got This - The Expert Guide To Parenthood Podcast is proudly supported by Mustela natural origin skincare, by parents' side since 1950.Follow us Social: Instagram: @parentsyouvegotthis_auThreads @parentsyouvegotthis_auTikTok: @partentsyouvegotthis_auFacebook: @parentsyouvegotthis__________________________________Parents You've Got This offers antenatal and postnatal parenting education and Masterclasses from the planning phase to early preschool. Learn more: ⁠⁠parentsyouvegotthis.com.au⁠⁠Credits: Producer Dean Thomas, Camera person Tim Hehir, Content and Hosts Parents You've Got This

In this episode of The Better Life, Dr. Pinkston sits down with Harvard-trained physician, consultant, and author Dr. Michael Myers Jr. to tackle the complex and often controversial topic of vaccines through the lens of sound science and clear data. With deep expertise as a former chief of primary care and pediatrics, Dr. Myers previews his upcoming book, The Vaccine Bible, and unpacks how immunization works as a reliable tool for long-term health and disease prevention. Together, Dr. Pinkston and Dr. Myers address the most common concerns shared by patient communities today, including the safety of combination shots, the reality of preservatives, and the thoroughly debunked links between vaccines and autism. They look closely at the critical role vaccines play in modern longevity—highlighting massive clinical wins like the shingles vaccine’s link to reduced dementia risk, and cancer-preventing tools like the Gardasil and Hepatitis B vaccines. Dr. Myers also breaks down the rapid development and safety of mRNA technology used during the COVID-19 pandemic. Tune in for an honest, evidence-based conversation that bridges the gap between integrative health practices and conventional immunology, empowering you to perform your own objective risk assessment for you and your family. https://www.drmikemyers.com/ See omnystudio.com/listener for privacy information.

Ken McCarthy returns to the podcast to discuss his latest book, The Hep B Chronicles: The Story of a Virus, a Vaccine, and Industrial-Sized Vats of Genetically Modified Baker's Yeast. In the book, he explores the history of hepatitis B, the development of the vaccine, and the broader questions he raises about public health policy, pharmaceutical influence, vaccine regulation, and informed consent… Drawing on historical research and his own analysis, Ken examines how hepatitis B vaccination became part of routine newborn care, the evolution of vaccine recommendations over the past century, and why he believes greater transparency and independent research are important for informed medical decision-making. This conversation covers: Why the hepatitis B vaccine is recommended for newborns. The history of hepatitis B and how public health strategies evolved throughout the 20th century. Ken's perspective on booster recommendations and vaccination policy. Questions surrounding pharmaceutical influence and regulatory oversight. The importance of informed consent and parental decision-making. Best known as one of the early pioneers of Internet commercialization, Ken organized one of the first conferences on the commercial potential of the World Wide Web in 1994 and has spent decades as an entrepreneur, educator, and author. In recent years, his work has focused on historical research, investigative journalism, and encouraging readers to explore complex topics from multiple perspectives. Connect with Ken: Brasscheck Personal Website Buy The Hep B Chronicles

Robert Gish, MD, on Advances in Managing Hepatitis B and D by Gastroenterology Learning Network

Sanjeev Krishnan spent thirty years arriving at one conclusion: the clean economy's binding constraint isn't technology, it's capital structure. He watched brilliant technologies, brilliant people and brilliant visions get broken on the wheel of misaligned capital — not because the science failed, but because the financing never fit what they were trying to build.That gap is the heart of this episode of SRI360. His core belief is simple: the thing holding back the clean economy is not technology. It is capital structure. Get the financing right, and the building can follow.I'm joined by Sanjeev Krishnan, Co-Founder and Managing Partner of S2G Investments, a nearly $3 billion platform across eight funds, investing at the seams of food, energy, and ocean systems. S2G has backed more than 120 companies. Sanjeev has spent his whole career on one question: how do you change an economic system using markets?Sanjeev was born in Bangalore in pre-liberalization India and moved to Grosse Pointe, Michigan, at age nine — his first time ever on a plane. He studied development economics, transferred to the London School of Economics, and joined JPMorgan just in time to watch the dot-com boom collapse from the inside. His team in Europe went from 120 people to 15. He was one of the 15 who kept their job.What came next taught him how capital really works in the physical world: building mobile networks across Africa, cutting the cost of a Hepatitis B vaccine by roughly 80–90% at the World Bank's IFC, and five hard years inside “clean tech 1.0,” watching good companies fail for reasons that had nothing to do with their technology. In 2014, he co-founded S2G with Lukas Walton.Today Sanjeev invests at the seams — the gaps between asset classes and between sectors that most investors overlook. In this conversation we cover why capital structure is the real constraint, how he thinks about the wave of AI and energy demand, and why he is betting on the oceans, the part of the planet we have barely measured.In this episode we discuss:Why capital structure, not technology, is what really holds back the clean economyThe “missing middle” — too big for venture, too small for private equity, and where good companies get strandedWhat “investing at the seams” of food, energy, and ocean systems actually meansFit-for-purpose capital, and why biotech figured it out but climate has notThe five forces behind his “Age of Adaptation” thesisWhy he reframes climate as a 10,000-year economic megatrend, not a moral crusadeHis bet on the oceans, and the company measuring water almost no one else canFeatured guest:Sanjeev Krishnan, Co-Founder and Managing Partner at S2G InvestmentsListen Next:AgTech Profits Meet Planet: Where Climate Impact and VC Returns AlignDiscover More from SRI360°:Explore all episodes of the SRI360° PodcastSign up for the free weekly email updateKey Takeaways:Capital structure is the constraint, not technology. Across thirty years, Sanjeev watched good companies with real products fail because the money backing them was shaped wrong for what they were building.The missing middle is where good companies get stranded. A business with real revenue and real profits can still be too capital-intensive for venture and too small for private equity control. Venture wants a power law. These companies just grow steadily. So nobody funds them. In May, S2G closed a billion-dollar fund built for exactly this gap.Fit-for-purpose capital means matching the money to the reality. US biotech built a system that can take an unproven, clinical-stage company public and attract hundreds of millions. Climate has never built its equivalent. That, Sanjeev argues, is the real gap.Every great transition needed a financial invention first. The joint stock company made oceanic trade possible. Bond syndicates built the railroads. The venture partnership funded the microchip. In each case someone built the financial container before the future arrived.Impact does not have to be concessionary. At the IFC, his team helped cut the cost of a Hepatitis B vaccine by roughly 80–90% — from $2.50 a vial — while margins stayed above 60–70%. Cheaper, faster, better, and profitable at the same time.Invest at the seams. The best opportunities sit between asset classes and between sectors, where a typical energy investor would dismiss it and a food investor would call it something else — so nobody underwrites it.Climate is a 10,000-year economic megatrend, not a moral crusade. Humans take useful energy and turn it into useful materials — fire, agriculture, fossil fuels. And the next chapter will still be extractive: it needs copper, cobalt, nickel, lithium.Busts are where the returns are made. You learn more in the bust cycles than the boom cycles. Markets overshoot both ways, and the companies that survive get forced into product-market fit and a real P&L.The oceans are the least measured part of the planet. We know more about space. Sanjeev co-founded Apeiron Labs in 2022 to close a data gap between 6 and 200 meters — data that matters for weather, offshore wind, insurance, and defense.Additional ResourcesSanjeev Krishnan LinkedIn: https://www.linkedin.com/in/sanjeev-krishnan-0b1148/Sanjeev Krishnan at S2G: https://www.s2ginvestments.com/team/sanjeev-krishnanS2G Investments: https://www.s2ginvestments.com/S2G “Financing Reality” report: https://www.s2ginvestments.com/insights/report-financing-realityBuilders Vision: https://www.buildersvision.com/Connect with SRI360°:Sign up for the free weekly email update: https://sri360.com/newsletter/Visit the SRI360° PODCAST: https://sri360.com/podcast/Visit the SRI360° WEBSITE: https://sri360.com/Follow SRI360° on X: https://twitter.com/SRI360Growth/Follow SRI360° on FACEBOOK: https://www.facebook.com/SRI360Growth/

The parasites most Americans think of as a tropical problem are already here; showing up as fatigue, asthma, and gut issues that standard tests keep calling "normal." An estimated 1 in 20 people may carry one and never know it.In this episode, Dr. Gabrielle Lyon sits down with Dr. Peter Hotez, a tropical-medicine physician and vaccine scientist, to discuss:Why toxocariasis, a worm shed by household dogs and cats, may affect 5–6% of the U.S. population, with larvae migrating through the lungs and brainWhy standard PCR panels come back negative and which specific tests (antibody, fecal, eosinophil count) to ask forHow to lower your risk at home, from deworming pets on a vet schedule to knowing which symptoms warrant a targeted testWhy the popular "worm therapy for autoimmune disease" idea has the relationship backwards, worms are a leading driver of IBD and asthma, not a cureWhether you've been told your labs are fine but still feel off, this conversation gives you a clear, evidence-based framework for what to test for and how to protect your family from infections hiding in plain sight.Thank you to our sponsors:BodyHealth - Use the code LYON20 to get 20% off your first order https://bit.ly/4f7ZqM5Our Place - Upgrade your kitchen with Our Place today. Visit https://bit.ly/4vT4cEr and use code DRYLON for 10% off sitewide. That's F-R-O-M-O-U-R-P-L-A-C-E DOT COM / D-R-L-Y-O-N and use code DRLYON for 10% off sitewide. With a 100-day trial, you can try it completely risk-free.Lucy Get 20% off your next order with code DRLYON at https://lucy.co/, or find yours in store at https://bit.ly/4ybQCxHExplore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Peter Hotez at:Website: https://peterhotez.org/Instagram: https://www.instagram.com/peterhotez/Book - “Science Under Siege: How to Fight the Five Most Powerful Forces that Threaten Our World” - https://a.co/d/07P0iANSConnect with Dr. Gabrielle Lyon:Instagram: https://www.instagram.com/drgabriellelyon/TikTok: https://www.tiktok.com/@drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction: trust in science and nutrition04:11 - Anti-parasitic drugs sold as snake oil06:43 - How misinformation gets weaponized18:23 - The turbo cancer claim debunked24:41 - Finding experts you can trust30:52 - Hepatitis B vaccine and how babies get infected31:56 - The 75 vaccine myth: eight diseases to seventeen35:42 - Why the COVID vaccine wasn't rushed40:18 - Toxocariasis: the worm in stray dogs and cats43:50 - Why parasite tests come back negative45:57 - Hookworm in rural Alabama48:05 - Eosinophils and how to test50:21 - Worm therapy for autoimmune is backwards54:19 - Deworming pets and family transmission57:19 - Liver fluke and bile duct cancer1:01:11 - Climate change and parasites in the US1:03:16 - Lyme, ticks, and genomic surveillance1:08:00 - Flu and COVID as cardiovascular threatsIf you found this episode valuable, share it with someone who would benefit from it.Disclaimers: This episode includes paid sponsorships.The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.

Could hepatitis B finally have a finite treatment option? Tatyana Kushner, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to break down the phase 3 B-Well data for bepirovirsen, the first agent to hit functional cure as a primary endpoint in chronic hepatitis B.The conversation covers the phase 3 B-Well 1 and B-Well 2 results, published in the New England Journal of Medicine and presented at EASL 2026, and why quantitative HBsAg testing is becoming essential to patient selection ahead of a potential approval. Kushner, Reau, and Brown also work through what functional cure actually means for patients, how it compares to spontaneous HBsAg loss, and what dosing and monitoring are likely to look like given signals for ALT elevation and renal effects seen in the trials. They discuss which patients are unlikely to be candidates, including those with cirrhosis or decompensated liver disease, and close with a look at what an approval could mean for hepatitis B screening rates and referral patterns between primary care and specialty hepatology.Bepirovirsen is not yet FDA approved. The FDA has accepted the New Drug Application for priority review, with a PDUFA goal date of October 26, 2026.For more: https://www.hcplive.com/view/liver-lineup-bepirovirsen-and-the-push-toward-functional-cure-in-hepatitis-b

Can a common Sexually Transmitted Infection (STI) lead to cancer?

In this episode of the LiverHealthPOD John, Will and Paul discuss new developments in Hepatitis B. Hepatitis B affects over 300 million people worldwide and remains the leading cause of liver cancer globally — yet for decades, treatment options have been limited to viral suppression rather than cure. In this episode we break down the exciting wave of new therapies that are changing what's possible for people living with chronic hepatitis B.If you like the Podcast don't forget to like and subscribe and send us an email with your stories to LiverHealthPOD.

In this episode, Bright and Anousha chat with Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, about the financial challenges people living with hepatitis B face in the U.S., including high medication costs, insurance barriers, and the ongoing struggle to access affordable, life-saving treatment.Note: Carl also shared an important update that at least one widely used hepatitis B medication is now available through Trump Rx for about $20 per month, offering a potentially more affordable option for some patients.Support the showOur website: www.hepb.orgSupport B Heppy!Social Media: Instagram - Twitter - Facebook

In the second episode of a 3-part series featuring audio from a live symposium, experts Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP, Patricia Stinchfield, MS, RN, PNP, and Jennifer M. Walsh, DNP, CPNP-PC, CNE explore effective strategies to counter common myths and misconceptions about vaccines, including actionable methods to champion the benefits and safety of pediatric vaccines. Visit the program page to view the full on-demand webcast and download the accompanying slides. Topics covered include:  Debunking the Link Between Vaccines and Autism  Reemergence of Previously Eliminated Diseases Building Trust With Parents and Caregivers Who and How to Debunk Vaccine Misinformation Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP Clinical Assistant Professor  Stony Brook University School of Nursing  Nurse Consultant  Immunize.org  Owner/NP Pediatric Nurse Practitioner House Calls Stony Brook, New York Patricia Stinchfield, MS, RN, PNP Independent Consultant Victoria, Minnesota (Retired) Senior Director, Infection Prevention & Control, Infectious Disease Children's Minnesota Immediate Past President, National Foundation for Infectious Diseases Minneapolis, Minnesota Jennifer M. Walsh, DNP, CPNP-PC, CNE Certified Pediatric Nurse Practitioner – Primary Care Assistant Professor School of Nursing George Washington University Washington, DC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the final episode of a 3-part series, featuring audio from a live symposium, experts Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP, Patricia Stinchfield, MS, RN, PNP, and Jennifer M. Walsh, DNP, CPNP-PC, CNE explore how to use “prebunking” strategies to inoculate patients and caregivers against vaccine misinformation and disinformation, as well as proven strategies to provide effective vaccine recommendations. Visit the program page to view the full on-demand webcast and download the accompanying slides. Topics covered include:  “Prebunking” Tactics Presumptive Recommendations Motivational Interviewing Principles  Responding to Arguments Against Immunization  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP Clinical Assistant Professor  Stony Brook University School of Nursing  Nurse Consultant  Immunize.org  Owner/NP Pediatric Nurse Practitioner House Calls Stony Brook, New York Patricia Stinchfield, MS, RN, PNP Independent Consultant Victoria, Minnesota (Retired) Senior Director, Infection Prevention & Control, Infectious Disease Children's Minnesota Immediate Past President, National Foundation for Infectious Diseases Minneapolis, Minnesota Jennifer M. Walsh, DNP, CPNP-PC, CNE Certified Pediatric Nurse Practitioner – Primary Care Assistant Professor School of Nursing George Washington University Washington, DC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week on the Super Fun Time Trivia Podcast, we discuss if Clifford The Big Red Dog's big red dog boner, how to genetically reverse the exciting feeling in your genitals, and the quickest way to pick up Hepatitis B in your long acryllic nails. Music Round: Pressure Patreon: Super Fun Time Trivia Website: superfuntimetrivia.com Facebook: superfuntimetrivia Instagram: superfuntimetrivia Twitter: @sftimetrivia Email: superfuntimetrivia@gmail.com Intro Music By David Dino White. Welcome to Super Fun Time Trivia: The known universe's only live improv comedy trivia podcast.

On today's Flyover Conservatives Show, we sit down with Dr. Troy Spurrill to discuss the health stories raising major questions across America — from sleep, stress, and HRV to RFK Jr.'s comments on vaccines, autism, and the Hepatitis B shot, plus the shocking report of an NIH Ebola expert allegedly caught smuggling dangerous pathogens. Dr. Spurrill breaks down why so many healthcare workers are frustrated with the current system, what functional medicine looks like, how parents can ask better questions, and why sleep may be one of the most overlooked keys to healing. This conversation covers medical freedom, Big Pharma, RFK Jr., gain-of-function concerns, sleep tracking, REM sleep, deep sleep, and the growing movement to restore common sense, clean data, and personal responsibility in healthcare.TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.com Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To ▶ https://flyovergold.comOr Call 720-605-3900 ► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.comDr. Troy Spurrill is the founder and CEO of Synapse Center for Health and Healing.  He started Synapse over 26 years ago with a vision to bring an integrative approach to healthcare through functional medicine, making Synapse an internationally known center for true health.He received a Bachelor's of Science in Molecular Biology from the University of Manitoba, and a Doctorate of Chiropractic from Northwestern Health Sciences University.  He has extensive training in Functional Neurology, Nutrition, and Applied Kinesiology. Dr. Troy is an author and international lecturer on wellness and brain based healing.  Dr. Troy SpurrillWEBSITE: www.officialsynapse.com -------------------------------------------

https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Screening Guidelines (1:46),Syphilis (2:25),Herpes (4:41),Chancroid (6:52),Gonorrhea (7:47),Chlamydia (9:11),Mycoplasma genitalium (11:00),Lymphogranuloma venereum (12:00),Pelvic Inflammatory Disease (13:16),Disseminated Gonococcal Infection (15:23),Trichomoniasis (16:37),Bacterial Vaginosis (18:03),Vulvovaginal Candidiasis (19:43),Human Papillomavirus (21:01),HIV (22:32),PrEP (24:06),Hepatitis B (25:29),Practice Questions (27:18)

In this episode, we examine the recent retraction of a 2010 study that suggested a link between neonatal hepatitis B vaccination and autism in boys. We break down the methodological flaws that led to its withdrawal, explore related research from the same authors and others, and dive into why establishing causal links between vaccines and autism remains extraordinarily complex. Autism is multifactorial—shaped by genetics, environment, and timing—and we discuss the broader scientific consensus while highlighting the importance of rigorous evidence in public health debates.

Viral hepatitis is an ongoing public health threat, despite the long-standing availability of effective vaccines for hepatitis A and B. Here, experts Paul Kwo, MD, Jewel Mullen, MD, MPH, MPA, FACP, and Su Wang, MD, MPH, FACP, discuss how to incorporate knowledge of hepatitis A and B risk factors and disease burden into patient counseling to enhance uptake of hepatitis A and B vaccines. Topics covered include: The burden of hepatitis A and B in the United States Risk factors for infection Current evidence-based recommendations for hepatitis A and B vaccination.  Follow along with the slides here, and get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul Y. Kwo, MD Professor of Medicine Director of Hepatology Stanford University School of Medicine Stanford, California Jewel Mullen, MD, MPH, MPA, FACP Associate Professor of Population Health and Internal Medicine University of Texas at Austin Dell Medical School Austin, Texas Su Wang, MD, MPH, FACP Medical Director, Center for Asian Health & Viral Hepatitis Programs Cooperman Barnabas Medical Center/RWJBarnabas-Rutgers Medical Group Assistant Clinical Professor, Rutgers New Jersey Medical Group Florham Park, New Jersey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Nurses Report with Ashley, Nicole, & David – Ashley and Nurse Nicole speak with Ken McCarthy about The Hep B Chronicles, vaccine marketing, serum hepatitis, iatrogenic harm, package inserts, and informed decision-making. The conversation challenges blind trust, explores public health narratives, and urges listeners to read, question, verify, and think before accepting newborn Hepatitis B vaccination claims today...

The Nurses Report with Ashley, Nicole, & David – Ashley and Nurse Nicole speak with Ken McCarthy about The Hep B Chronicles, vaccine marketing, serum hepatitis, iatrogenic harm, package inserts, and informed decision-making. The conversation challenges blind trust, explores public health narratives, and urges listeners to read, question, verify, and think before accepting newborn Hepatitis B vaccination claims today...

The U.S. and Iran reportedly reach a tentative deal to extend their ceasefire by 60 days, a judge declines to block Trump's order restricting mail-in voting, Mexico's congress backs a constitutional amendment adding foreign interference as grounds to annul elections, a deadly school fire kills 16 in Kenya, the U.N. projects a 75% chance that Earth will surpass the 1.5°C threshold by 2030, the DOJ launches a criminal investigation into E. Jean Carroll related to her Trump testimony, a review warns that the U.K.'s youth unemployment crisis could hit 1.25 million by 2031, the EU fines Temu $232 million for failing to stop the sale of illegal and unsafe products, the OpenAI Foundation commits $250 million to help workers and economies adapt to AI disruption, and a new drug shows promise as a functional cure for Hepatitis B infections. Sources: Verity.News

This episode covers hepatitis B.Notes: https://zerotofinals.com/paediatrics/infectiousdisease/hepb/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

In episode 77 of Going anti-Viral, Dr Debika Bhattacharya joins host Dr Michael Saag to discuss the management of hepatitis B virus (HBV) infection and vaccination. Dr Bhattacharya is a Clinical Professor at the University of California Los Angeles (UCLA) David Geffen School of Medicine and specializes in the management of HIV and HIV/viral hepatitis coinfection and sees patients with viral hepatitis and HIV/viral hepatitis coinfection at UCLA and its affiliated clinics. Her research involves viral hepatitis clinical therapeutics and long-term clinical outcomes in persons with HIV/viral hepatitis or viral hepatitis alone. Dr Saag and Dr Bhattacharya discuss HBV infection and vaccination, especially among people with HIV addressing prevalence, serology interpretation, vaccination strategies, and management of hepatitis B in the context of HIV treatment. They also reinforce the need for more research into therapies that will lead to a cure for hepatitis B. 0:00 – Introduction 1:16 – Understanding hepatitis B and its impact on people with HIV  2:56 – Vaccination strategies for hepatitis B 4:53 – Interpreting hepatitis B serology results 8:38 – Vaccination protocols and recommendations 13:19 – Managing patients with hepatitis B 14:29 – Long-acting therapies and hepatitis B risks 17:29 – Screening and monitoring for hepatitis B 19:01 – Navigating core antibody positivity 23:36 – The importance of antibody titers 28:23 – Final thoughts on hepatitis B management Resources: Going-anti-Viral: Episode 31 - Will we ever have a cure for hepatitis B? - Dr Kenneth ShermanYouTube:  https://youtu.be/yh48RFOrISk Apple Podcasts:  https://podcasts.apple.com/us/podcast/episode-31-will-we-ever-have-a-cure-for-hepatitis-b/id1713226144?i=1000677466892 __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

According to Hepatitis Australia, around 220,000 people in Australia are living with chronic Hepatitis B, with 4–5% of cases linked to people born in the Philippines. - Ayon sa Hepatitis Australia, tinatayang nasa 220,000 ang may chronic Hepatitis B sa bansa, 4 hanggang 5 porsyento sa kabuuang bilang ay mula sa Pilipinas.

You can connect with Marilyn Bulloch on LinkedIn here.Read more insights about hepatitis B throughout Hepatitis Awareness Month at Pharmacy Times' Hepatitis Resource Center.Episode Timestamps:1:05: Introduction2:08: Current Disease Burden of Hepatitis B3:55: Risk Landscape for Adults7:20: Link Between Chronic Hepatitis B and Liver Cancer10:25: Expanded Vaccine Recommendations13:25: The Role of Pharmacists in Vaccine Counseling16:40: Why Shorter Conversations Are Better17:55: Advantages of 2-Dose Schedule20:40: Closing the Adult Hepatitis B Immunization Gap23:50: A Patient Counseling Scenario25:25: Closing Thoughts

Episode 223: Oncogenic Viruses Introduction Mehr: Hi everyone, welcome back to the Rio Bravo qweek podcast. Back by popular demand is Me, Mehr Boparai a third-year medical student at COMP-NW. Here with me is Jeremy Pan from COMP who is also a third-year medical student. How are you doing Jeremy? Jeremy: I'm doing great Mehr.Thanks for the kind intro; we had a fun time this morning doing street medicine and had some practice giving Toradol injections and wound dressings. So excited to be back for another podcast episode this afternoon! Mehr: This week, we are moving away from bacteria and antibiotics and diving deeper into cancer-causing viruses. Jeremy: Yes, and if you are interested at all in public health, this is one of those areas where medicine overlaps with public health in a really tangible way. I think one of the most underappreciated aspects of this topic is that we have vaccines that can prevent many of these cancers. If you told someone 50 years ago we'd be vaccinating against cancer, they probably wouldn't believe you! It's amazing to see how far medicine has come. How viruses cause cancer: Jeremy: Before jumping into specific viruses, I always think having a mechanism-based framework makes everything stick better. Mehr: Right, because they don't all cause cancer the same way. Medicine can never be easy huh? Jeremy: Yea…this career really is just a lifetime of discovery. So just to start, in broad terms, we can think of three main buckets of how viruses can cause cancer: Direct oncogenesis where viral proteins interfere with tumor suppressors like P53 and Rb. We will go over their specific mechanisms a little later in the discussion. Mehr:  Chronic inflammation where viruses cause repeated injury through production of reactive oxygen species. They also increase the chance of mutation through repeated DNA replication, leading to cancer.  Jeremy: Immune evasion or suppression leads to decreased tumor surveillance. What this means essentially is that our immune system is constantly removing abnormal cells before they become cancerous. This is completed by CD8 T cells and natural killer, or NK, cells. CD8 T cells recognize abnormal peptides presented on Major Histocompatibility Complex, or MHC, class I molecules and induce apoptosis in those cells. Mehr: And NK cells step in when cells decide to stop expressing MHC I, which abnormal cells like to hide to avoid being caught. So just to reiterate, there are two layers to dissect here: if a cell looks suspicious with an abnormal MHC, CD8 T-cells kill them. If the abnormal cell decides to hide its MHC, then the NK cell will kill it instead. Jeremy: So, for the final big picture, we can think of oncogenic viruses as either disabling tumor suppression, causing chronic damage over time through inflammation, and weakening the immune system's ability to catch cancer in time before it develops. HPV Mehr: Let's start with one of the most common viruses afflicting our population – Human Papilloma Virus otherwise known as HPV.  Jeremy: Right, this notorious virus is probably the most clinically impactful oncogenic virus. The key players HPV utilizes are proteins E6 and E7. Mehr: Right! E6 binds to and inhibits p53, which normally acts to induce cell cycle arrest, and E7 inhibits Rb, which normally acts as a tumor suppressor gene that inhibits the G1 to S phase transition in a normal cell cycle. Jeremy: So essentially, we are losing both apoptosis and losing cell cycle control at the same time. What is interesting about HPV is that persistent infection, not just exposure to the virus, is what drives cancer risk.  Mehr: Exactly, most HPV infections clear on their own, but the ones that persist are the problem. Clinically, many end up being asymptomatic. However, for high-risk infections, we can see genital warts that can itch, feel tender, or cause abnormal vaginal bleeding and discharge. Patients are sometimes not able to have a vaginal delivery because of the warts that are present along their genital tract. We can also see warts on the hands and fingers or plantar surface of our feet. Jeremy: Another interesting point is that we are also seeing a shift where there are more cases of oropharyngeal cancers in younger, non-smoking patients. This is why if we see an abnormal neck lymph node or persistent sore throat after swallowing in a young patient, HPV should definitely be on the differential.  Mehr: Screening is very important as well! We typically discover high-risk HPV infections through routine Pap smears and other HPV specific tests through DNA PCR and RNA tests. We also encourage vaccination for effective prevention of both genital warts and high-risk HPV-related cancers. There was also a study in Scotland where there were zero cases of HPV in adults who received the vaccine between 12-13 years of age! Which is crazy!  EBV HBV & HCV Mehr: Now let's shift to viruses that affect the liver, Hepatitis B virus and Hepatitis C virus. Jeremy: Both are strongly associated with hepatocellular carcinoma, but they actually get there in slightlydifferent ways. Mehr: Right. Hepatitis B is a DNA virus that can integrate directly into the host genome, which can disrupttumor suppressor genes and promote oncogenesis. Jeremy: Whereas Hepatitis C is an RNA virus, so it doesn't integrate into the host genome. Instead, it causes chronic inflammation Over time, that leads to repeated cycles of hepatocyte injury and regeneration, along withoxidative stress from reactive oxygen species, which increases the risk of DNA mutations. Mehr: One really important clinical pearl is that Hep B can actually cause hepatocellular carcinoma evenwithout cirrhosis. Whereas with Hep C, the pathway is usually chronic inflammation → fibrosis → cirrhosis → dysplasia→ cancer.  Jeremy: So, screening becomes really important for both of these viruses. For high-risk patients—like those with chronic hepatitis or cirrhosis—we typically dosurveillance with liver ultrasound every 6 months, sometimes with alpha-fetoprotein levels to see if it is elevated. Mehr: From a prevention standpoint, the Hep B vaccine is a huge win. It significantly reduces the risk ofhepatocellular carcinoma. For Hep C, we don't have a vaccine, but direct-acting antivirals can actually cure the infection andreduce long-term cancer risk, which is why we screen between ages 18-79  nowadays. Global Hep B and C account for 65% of all HCC cases! So, it makes sense that primary care itself is increasing the treatment of Hep C cases as well since it is easier to prescribe and that you want to be treated ASAP.  Jeremy: Yea, the ability to treat Hep C is so beneficial to population health. Now let's say you have a patient who develops hepatocellular carcinoma, options can include surgicalresection, liver transplantation, local therapies, or systemic treatments depending on stage.  Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!  __________________________________ References: Barry H. C. (2024). Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received at Least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age. American family physician, 110(2), 201–202. https://pubmed.ncbi.nlm.nih.gov/39172683/ Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

Listen as Bright Ansah, patient advocate, describes his experience with being diagnosed with chronic hepatitis B as a recent immigrant to the United States and the unique barriers to treatment faced by the African immigrant community. Through his story, learn how healthcare professionals can reduce these barriers for this key population. Topics covered include: Key barriers to care for African immigrant patients Myths and misconceptions about HBV in the African immigrant community Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to program page: https://bit.ly/4uz25Vc Presenter: Bright Ansah  HBV Patient Advocate Frederick, Maryland Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis B virus (HBV) infection affects around 254 million people worldwide and causes more than 1 million deaths annually. Author Anna Lok, MD, from the University of Michigan discusses HBV transmission, screening, and treatment with JAMA Associate Editor Beverly Forsyth, MD. Related Content: Hepatitis B Hepatitis B Virus Treatment Gaps in the US Tenofovir and Hepatitis B Virus Transmission During Pregnancy US Newborn Hepatitis B Virus Vaccination Rates

For US veterans, support for continued engagement in hepatitis B (HBV) care has been lacking. Listen in as Richelle M. Gaiter, DMSc, MPAS, Med, shares her experiences with HBV care as an Air Force veteran and what can be done to improve HBV care for veterans and civilians alike. Topics include:  Key barriers to HBV care for US veterans What has improved in the last decade Strategies for improved engagement in care Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to program page:https://bit.ly/4vAqSJT Presenter: Richelle M. Gaiter, CMSGT Retired USAFR, DMSc, MPAS, Med Family Medicine, Prevention, Patient Education Crescent City, California Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Anousha and Bright speak with Dr. Chloe Thio and Dr. David Thomas, academic medical researchers at the Johns Hopkins School of Medicine, about a new NIH grant supporting a Johns Hopkins–led consortium focused on finding a cure for hepatitis B. They discuss the goals of the $24 million award, the importance of collaborative science, and what this investment could mean for the future of hepatitis B research and for people living with the disease.Support the showOur website: www.hepb.orgSupport B Heppy!Social Media: Instagram - Twitter - Facebook

The vaccination schedule for your baby can feel daunting. It also may seem a little strange,  you might wonder why a newborn needs to be protected against Hepatitis B? Between frequent visits to the pediatrician and fears you might have over adverse reactions to the vaccines, many parents wonder how they can best support their child.  In this episode of Yoga|Birth|Babies I speak with holistic pediatrician Dr. Ana-Maria Temple about newborn and childhood vaccinations. In an easily digestible manner, she explains the vaccines babies are given and why they are given at such a young age. We discuss the possibility to delay certain vaccines and why a parent might consider doing that. Dr. Temple also offers resources and questions you might ask your pediatrician to get everyone working together and ensure care is aligned with your family's goals. As Dr. Temple says “If you understand the why, you can then make decisions and choices.”  Get the most out of each episode by checking out the show notes with links, resources and other related podcasts at: prenatalyogacenter.com Don't forget to grab your FREE guide, 5 Simple Solutions to the Most Common Pregnancy Pains HERE  If you love what you've been listening to, please leave a rating and review! Yoga| Birth|Babies (Apple) or on Spotify! To connect with Deb and the PYC Community:  Instagram & Facebook: @prenatalyogacenter Youtube: Prenatal Yoga Center Learn more about your ad choices. Visit megaphone.fm/adchoices

What actually happens to your baby in the first 24–48 hours after birth, and which newborn interventions should you say yes or no to?In this episode, we break down 14 common newborn interventions and procedures parents may be offered right after delivery. From delayed cord clamping and suctioning to vitamin K, hepatitis B, erythromycin eye ointment, newborn metabolic screening, hearing and heart tests, circumcision, jaundice, early bathing, and pediatric follow-up, we explain what these interventions are, why they're offered, and what parents should understand before birth.Whether you're planning a hospital birth, home birth, or birth center delivery, this conversation will help you make informed decisions about newborn care and know what questions to ask when creating your birth plan.00:00 Trailer + intro01:13 Why newborn interventions matter03:44 Delayed cord clamping09:23 Rubbing and suctioning after birth14:26 Swaddling, hats, and skin-to-skin18:37 The golden hour and delaying newborn exams21:10 Vitamin K shot vs oral vitamin K29:44 Hepatitis B vaccine at birth34:07 Erythromycin eye ointment36:57 Newborn metabolic screening / heel prick / PKU test39:19 Newborn blood sugar testing41:42 Hearing test and congenital heart disease screening46:36 Circumcision considerations47:32 Early bath and newborn microbiome52:31 Newborn jaundice explained56:39 Breastfeeding jaundice vs breast milk jaundice59:04 Pediatrician visits and delayed vaccine schedules01:05:39 Closing thoughtsResources From This Episode:Vax Dilemmas: Hesitancy, Studies, and Alternate Schedules with Dr. Joel Gator Warsh | Ep. 109 - https://youtu.be/d72t0Dv18Ok?si=OawY6xJOcWhy0w44Vaccines From A Neurodevelopmental Perspective with Dr. Ari Calhoun | Ep. 52 - https://podcasts.apple.com/us/podcast/healthy-as-a-mother/id1663942916?i=10006483825895 Things That Ruin Breastfeeding | Ep 146 - https://youtu.be/BQgB9rQ_Msk?si=fwrB0QJ1DvfzrrUmBreastfeeding and Trying To Conceive | Ep 113 - https://youtu.be/vRXXioExVh8?si=epAYIrJeqe197ftJBreastfeeding: What to KNOW before your baby is born | Ep 10 - https://podcasts.apple.com/us/podcast/healthy-as-a-mother/id1663942916?i=1000601146225Find more from Dr. Leah:Dr. Leah Gordon | InstagramDr. Leah Gordon | WebsiteWomanhood Wellness | WebsiteFind more from Dr. Morgan:Dr. Morgan MacDermott | InstagramDr. Morgan MacDermott | WebsiteUse code HAAM and save 10% at FondUse code HEALTHYMOTHER and save 15% at RedmondFor 20% off your first order at Needed, use code HEALTHYMOTHERSave $260 at Lumebox, use code HEALTHYASAMOTHER

Send Zorba a message!Zorba lays out a plan for taking action regarding the CDC rolling back universal Hepatitis B vaccination recommendations for newborns, which goes against widespread public health consensus.(Recorded December 5, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

In this podcast, Kyle welcomes Aaron Siri, a prominent legal advocate known for his work with the Informed Consent Action Network (ICAN) and Del Bigtree's Highwire, who has been influential in uncovering pharmaceutical industry practices. The conversation revolves around Siri's new book, 'Vaccines. Amen,' which critiques the almost religious zeal with which vaccines are regarded and delves into various controversial aspects of vaccine safety and policy. Siri discusses the deficiencies in safety testing of vaccines, such as the Hepatitis B vaccine trials involving infants, and highlights how the 1986 National Childhood Vaccine Injury Act shifted the responsibility of vaccine safety from manufacturers to the federal government, resulting in a lack of accountability. The conversation also explores the history and efficacy of the Measles vaccine, potential long-term health impacts of vaccines, and the broader implications of governmental and pharmaceutical industry practices. Kyle and Siri emphasize the importance of individual choice and informed consent in vaccination decisions, criticizing the lack of transparency and the ethical implications of government-mandated vaccines. The discussion concludes with reflections on the future of vaccine policy and the importance of maintaining personal freedoms and rights. Aaron Siri is the managing partner of Siri and Glimstad, where he focuses on civil rights, informed consent, class actions, and complex civil litigation. His work includes challenging medical mandates, defending parental rights, representing whistleblowers, and forcing government transparency, including litigation that compelled the FDA to release Pfizer COVID 19 records. Aaron previously practiced at Latham and Watkins and clerked for the Chief Justice of the Supreme Court of Israel. He earned his law degree from UC Berkeley School of Law, where he served as Editor in Chief of the Berkeley Business Law Journal.   From Kyle: The Community is coming! Click here to learn more   Connect with Aaron here: Instagram Website Siri & Glimstad LLP   Our Sponsors: Let's level up your nicotine routine with Lucy. Go to Lucy.co/KKP and use promo code (KKP) to get 20% off your first order. Lucy offers FREE SHIPPING and has a 30-day refund policy if you change your mind.   Connect with Kyle: I'm back on Instagram, come say hey @kylekingsbu Twitter: @kingsbu Our Farm Initiative: @gardenersofeden.earth Odysee: odysee.com/@KyleKingsburypod Youtube: https://www.youtube.com/@Kyle-Kingsbury Kyle's Website: www.kingsbu.com - Gardeners of Eden site If you enjoyed this podcast, please subscribe & leave a 5-star review with your thoughts!

In this episode, Lindsey sits down with pediatrician Dr. Joel Warsh a.k.a. Dr. Gator, author of Between a Shot and a Hard Place, for the conversation every mom needs to hear. Get an honest look at vaccine safety, parental autonomy, and trusting your intuition in a world of conflicting advice. Ahead, Lindsey + Dr. Gator dive into the chronic illness epidemic—exploring everything from the long-term effects of vaccines to the rise in allergies, autism, and autoimmune conditions in kids today. You'll learn why asking questions isn't “woo-woo”—it's essential to make informed choices.  If you've ever felt judged for going “off schedule” or considered an alternative vaccine approach, this episode brings nuance, compassion, and real data. From toxic ingredients to finding the right doctor, don't miss this must-listen for parents who care about wellness, safety, and sovereignty. We also talk about: The real reasons vaccine schedules have skyrocketed in recent decades What ingredients in vaccines could mean for your child's health Why most doctors won't see families who want alternative vaccine schedules—and what to do about it Debunking the “safe and effective” narrative + what parents actually want to know The myth vs. reality of vaccine injury reporting (VAERS) + what gets missed Pros + cons of delaying or spacing out vaccines—and how to weigh the risks The truth about Hepatitis B at birth, polio, and why some shots might be less urgent than you think Autism, MMR, and the data gaps that you need to hear about Finding “your people” as a parent when conversations around vaccines feel taboo Empowerment tips on trusting your gut, advocating for your child, and demanding better research Resources: Instagram: @drjoelgator X: @drjoelgator Book: www.theshotbook.com Order our book, Almost 30: A Definitive Guide To A Life You Love For The Next Decade and Beyond, here: https://bit.ly/Almost30Book.  Sponsors: Fatty15 | Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/ALMOST30 and use code ALMOST30 at checkout.  Ka'Chava | Go to kachava.com and use code ALMOST30 for 15% off your next order. Hero Bread | Hero Bread is offering 10% off your order. Go to hero.co and use code ALMOST30 at checkout. Revolve | Shop at REVOLVE.com/ALMOST30 and use code ALMOST30 for 15% off your first order. #REVOLVEpartner BetterHelp | This episode is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/almost30 and get on your way to being your best self with 10% off your first month. Chime | It just takes a few minutes to sign up. Head to Chime.com/ALMOST30. Paleovalley | Head to paleovalley.com/almost30 for 15% off your order! Our Place | Visit fromourplace.com/ALMOST30 and use code ALMOST30 for 10% off sitewide.  To advertise on this podcast please email: partnerships@almost30.com. Learn More: https://almost30.com/about https://almost30.com/morningmicrodose https://almost30.com/book Join our community: https://facebook.com/Almost30podcast/groups https://instagram.com/almost30podcast https://tiktok.com/@almost30podcast https://youtube.com/Almost30Podcast Podcast disclaimer can be found by visiting: almost30.com/disclaimer.  Almost 30 is edited by Garett Symes and Isabella Vaccaro. Learn more about your ad choices. Visit megaphone.fm/adchoices

OA1227 - Come play the worst ever round of the Connections game and figure out what on earth Tuskegee Alabama, the CDC, Southern Denmark University, and the West African country of Guinea-Bissau all have in common, as RFK Jr. continues his campaign of “just asking questions” that we already have the answer to. Black men untreated in Tuskegee syphilis study. Heller, J. (July 25, 1972; republished May 10, 2017). Associated Press. The untreated syphilis study at Tuskegee timeline. Centers for Disease Control. (September 4, 2024). 45 CFR 46 Protection of Human Subjects. (Department of Health and Human Services regulations to implement the National Research Act and create Institutional Review Board policies). Hepatitis B. World Health Organization (July 23, 2025). Should the U.S. model its vaccine policy on Denmark's? Experts say we're nothing alike. Godoy, M. (December 26, 2025). NPR. RFK Jr. overhauls childhood vaccine schedule to resemble Denmark's in unprecedented move. Lovelace Jr., B., Edwards, E., Fattah, M., & Bendix, A. (January 5, 2026). NBC News. What is actually the emerging evidence about non-specific vaccine effects in randomized trials from the Bandim Health Project? Støvring, H., Ekstrøm, C.T., Schneider, J.W., & Strøm, C. (2025). Vaccine, 68, 1-4. Notice of award of a single source unsolicited grant to fund University of Southern Denmark (SDU). Department of Health and Human Services. (December 15, 2025). U.S. plan for $1.6m hepatitis B vaccine study in Africa called ‘highly unethical'. Schreiber, M. & Lay, K. (December 19, 2025). The Guardian. CDC awards $1.6 million for hepatitis B vaccine study by controversial Danish researchers. Szabo, L. (December 18, 2025). Center for Infectious Disease Research and Policy. CDC funds controversial hepatitis B vaccine trial in African newborns. Offord, C. (December 18, 2025). Science Insider. Research ethics and compliance support. Southern Denmark University. Further reading: Qiao, H. (2018). A brief introduction to institutional review boards in the United States. Pediatric Investigation, 2, 46-51. U.S. Department of Health and Human Services. International compilation of human research standards. https://www.hhs.gov/ohrp/international/compilation-human-research-standards/index.html University of North Carolina. Nuremberg Code. https://research.unc.edu/human-research-ethics/resources/ccm3_019064/ Torrance, R.J., Mormina, M., Sayeed, S., Kessel, A., Yoon, C.H., & Cislaghi, B. (2024). Is the U.N. receiving ethical approval for its research with human participants? Journal of Medical Ethics, 51, 1-4. Barchi, F. & Little, M.T. (2016). National ethics guidance in Sub-Saharan Africa on the collection and use of human biological specimens: A systematic review. BMC Medical Ethics, 17, 1-25. Salhia, B. & Olaiya, V. (2020). Historical perspectives on ethical and regulatory aspects of human participants research: Implications for oncology clinical trials in Africa. JCO Global Oncology, 6, 959-965. Check out the OA Linktree for all the places to go and things to do!

A trip to get an updated tetanus shot led to the realization that Justin never got a Hepatitis B vaccine. So Dr. Sydnee explains what exactly is Hep B, the recent headlines surrounding the vaccine, why do people usually get this vaccine as babies – and why didn't Justin get it?Music: "Medicines" by The Taxpayers https://taxpayers.bandcamp.com/Harmony House: https://harmonyhousewv.com/

The Centers for Disease Control and Prevention is likely to reverse its long-standing recommendation that all newborns be immunized against Hepatitis B. We spoke with Demetre Daskalakis, the former director of the CDC's National Center for Immunization and Respiratory Diseases, about the long-term impact of the proposed changes, how parents should respond, and whether we should all worry about vaccine recommendations coming from this administration.And in headlines, the Supreme Court could greatly expand the presidential power over independent federal agencies, Paramount launches a hostile takeover bid to pry Warner Bros. Discovery from Netflix, and President Donald Trump saves American farmers from tariffs by using… tariffs?Show Notes: Call Congress – 202-224-3121Subscribe to the What A Day Newsletter – https://tinyurl.com/3kk4nyz8What A Day – YouTube – https://www.youtube.com/@whatadaypodcastFollow us on Instagram – https://www.instagram.com/crookedmedia/For a transcript of this episode, please visit crooked.com/whataday Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Federal scrutiny of Minnesota's public programs intensifies as investigators uncover expansive fraud tied to the state's Somali community. A federal advisory panel votes to revise the Hepatitis B newborn vaccine schedule, igniting fierce backlash from legacy media and some former health officials. Netflix strikes a blockbuster deal to buy Warner Bros., a move poised to upend Hollywood and reshape the future of theatrical movies. President Trump publicly lashes out at Democratic Congressman Henry Cuellar just days after granting him and his wife full pardons.  Herald Group: Learn more at https://GuardYourCard.com Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A CDC advisory panel has voted to roll back Hepatitis B vaccines for newborns. If approved, it could reverse 30 years of gains in fighting the liver disease. We also look how Hollywood is responding Netflix purchasing Warner Bros. And we look at a series of economic indicators and how the Federal Reserve might respond to in their meeting next week.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy